(Q39675259)

13 September 2017

1 reference

title

Symposium on antimicrobial agents. Metronidazole (English)

1 reference

13 September 2017

J E Rosenblatt

1

1 reference

PubMed ID

3312851

13 September 2017

R S Edson

series ordinal

2

1 reference

PubMed ID

3312851

13 September 2017

language of work or name

English

0 references

publication date

1 November 1987

1 reference

13 September 2017

1 reference

13 September 2017

62

1 reference

13 September 2017

11

1 reference

13 September 2017

1013-1017

1 reference

Metronidazole in amoebic dysentery and amoebic liver abscess

13 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

Metronidazole in giardiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

TREATMENT OF VINCENT'S STOMATITIS WITH METRONIDAZOLE.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

Bactericidal Activity of Five Antimicrobial Agents against Bacteroides fragilis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

Anaerobic vaginosis (non-specific vaginitis): clinical, microbiological, and therapeutic findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

The interaction of reduced metronidazole with DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

Activity of metronidazole and its hydroxy and acid metabolites against clinical isolates of anaerobic bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

In vitro activity of the two principal oxidative metabolites of metronidazole against Bacteroides fragilis and related species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

Comparative efficacy of 10 antimicrobial agents in experimental infections with Bacteroides fragilis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

Susceptibility of Anaerobic Bacteria to Metronidazole: Relative Resistance of Non-Spore-Forming Gram-Positive Baccilli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

Metronidazole in anaerobic infections: a review of its activity, pharmacokinetics and therapeutic use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

Unique Bactericidal Action of Metronidazole Against Bacteroides fragilis and Clostridium perfringens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

Mechanisms of Resistance and Resistance Transfer in Anaerobic Bacteria: Factors Influencing Antimicrobial Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

Susceptibility of anaerobic bacteria to 23 antimicrobial agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

Antimicrobial susceptibilities of 1,292 isolates of the Bacteroides fragilis group in the United States: comparison of 1981 with 1982

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

Survey of anaerobic susceptibility patterns in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

Increasing resistance of Bacteroides fragilis group strains to metronidazole in Spain between 1977 and 1982.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

Isolation of Bacteroides strains with reduced sensitivity to 5-nitroimidazoles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

Comparative evaluation of the 2-methyl-5-nitroimidazole compounds dimetridazole, metronidazole, secnidazole, ornidazole, tinidazole, carnidazole, and panidazole against Bacteroides fragilis and other bacteria of the Bacteroides fragilis group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

Treatment with metronidazole of 48 patients with serious anaerobic infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

Bacteroides fragilis endocarditis, bacteremia and other infections treated with oral or intravenous metronidazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

Metronidazole in surgical infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

Activity of metronidazole against Escherichia coli in experimental infra-abdominal sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

Therapeutic efficacy of 29 antimicrobial regimens in experimental intraabdominal sepsis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

In-vitro and in-vivo activity of metronidazole against Gardnerella vaginalis, Bacteroides spp. and Mobiluncus spp. in bacterial vaginosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

Prophylactic peroperative intravenous metronidazole in elective colorectal surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

In vitro drug susceptibility and doses of metronidazole required for cure in cases of refractory vaginal trichomoniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

Treatment of Parasitic Infections of Travelers and Immigrants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

Artifactual Depression of Serum Glutamic Oxaloacetic Transaminase by Metronidazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

Experimental Induction of Hepatomas, Mammary Tumors, and Other Tumors With Metronidazole in Noninbred Sas:MRC(WI)BR Rats2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

Mutagenicity of metronidazole: Activation by mammalian liver microsomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

Detection of carcinogens as mutagens in the Salmonella/microsome test: assay of 300 chemicals: discussion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

Lack of evidence for cancer due to use of metronidazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

Cancer after metronidazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965074-5

10.1016/S0025-6196(12)65074-5

7 January 2021

Identifiers

DOI

1 reference

13 September 2017

1 reference

PubMed ID

3312851